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ABSTRACT
Monocyte chemoattractant protein-1 is critical for monocyte recruitment to the lungs
in response to bacterial infection. MCP-1 is also essential for protective neutrophil
recruitment to the lungs during Escherichia coli and Klebsiella pneumoniae infection.
Staphylococcus aureus pneumonia, specifically strain USA300, carries a high morbidity and
mortality rate and is an important pathogen in hospital/ventilator and community acquired
pneumonia. In the current study, we investigated the role of MCP-1 in pulmonary innate
immunity to S. aureus in C57Bl/6, MCP-1-/- and MCP-1 AB blocked mice. As compared to
C57Bl/6, MCP-1-/- mice showed increased concentrations of neutrophils in the airways and
lung parenchyma as assessed by nucleated cell concentrations in BALF, myeloperoxidase
activity (MPO) in lung tissue, and lung histopathology, and increased concentrations of the
pro-inflammatory cytokines TNF-α and IL-6. However, this increase in inflammatory
cytokines and augmented neutrophilic response did not correlate with increased bacterial
clearance, as determined by CFUs from BALF, lung, liver and spleen. MCP-1 AB blocked
mice trended towards higher BALF nucleated cell counts and MPO activity in lung tissue,
but were not significantly different from negative controls. In conclusion, MCP-1 appears to
be differentially regulated during bacterial pneumonia, and in an S. aureus model, MCP-1-/mice have moderately enhanced neutrophilic inflammation which does not improve bacterial
clearance.

!
!

viii

CHAPTER 1
INTRODUCTION
!

Staphylococcus!aureus!is!a!leading!cause!of!bacterial!infection!worldwide,!and!in!

the!United!States!is!the!principle!isolate!from!hospitalIassociated!bacterial!infections.1!!
Among!the!spectrum!of!S.!aureus!disease!manifestations,!the!majority!are!skin!and!soft!
tissue!infections,!however!other!sites!including!the!bloodstream!and!lower!respiratory!
tract!are!also!wellIdescribed.1!Notably,!while!pneumonia!is!far!less!common!than!soft!
tissue!infection,!it!is!responsible!for!the!majority!of!fatalities!associated!with!methicillin!
resistant!strains!of!S.!aureus!(MRSA).!!In!2005!MRSA!strains!were!responsible!for!
18,000!deaths!in!the!U.S.,!more!than!¾!of!which!were!due!to!pneumonia.2!
!

On!the!basis!of!pulse!field!gel!electrophoresis!(PFGE),!the!CDC!categorized!the!

most!common!isolates!of!S.!aureus!using!the!USA!naming!system,!which!currently!
includes!strains!USA100IUSA1200,!all!of!which!display!methicillin!resistance!with!the!
exception!of!strains!USA900!and!USA1200.3!In!addition!to!PFGE!classification,!S.!aureus!
strains!are!often!grouped!according!to!epidemiologic!associations,!namely!community!
acquired!infections!!(CAIMRSA),!or!those!associated!with!hospitalization!or!ventilator!
support!(HA/VAPIMRSA).!
!

Strain!USA300,!initially!described!in!the!1990s!as!a!sporadic!cause!of!community!

acquired!infection!among!healthy!individuals,!continues!to!be!the!leading!cause!of!CAI
MRSA!infections.2!Since!that!time,!however,!it!has!also!been!described!as!a!principle!
strain!in!HA/VAPIMRSA!cases.!!In!a!2012!analysis!of!MRSA!isolates!from!251!intensive!
care!unit!(ICU)!patients!USA300!was!the!second!most!common!isolate!(23.9%).4!
HA/VAPIMRSA!pneumonia!has!a!high!mortality!rate!(up!to!37%!in!one!study)!
compared!to!other!HA!bacterial!pneumonias,!and!is!also!a!large!drain!on!health!care!
!
!
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resources/costs,!with!HA/VAPIMRSA!cases!averaging!$8,000!more!in!medical!costs!
than!pneumonia!caused!by!methicillin!sensitive!strains.4I6!
!

Gross!and!histopathologic!pulmonary!findings!in!USA300!pneumonia!are!

distinctive!among!bacterial!pathogens,!consisting!of!severe!hemorrhage!and!necrosis!
with!intralesional!bacteria!but!no!appreciable!suppurative/neutrophilic!response.7!!The!
severity!of!USA300!pneumonia!is!not!reliant!solely!on!the!immunocompromised!nature!
of!hospitalized!individuals,!as!it!causes!similar!lesions!in!otherwise!healthy!individuals!
acquiring!infections!as!a!result!of!CAIMRSA.!!Methicillin!resistance!is!another!unlikely!
explanation,!as!many!other!common!HA/VAP!MRSA!strains!actually!display!broader!
antibiotic!resistance!to!multiple!drug!classes.4!!Ultimately!several!virulence!factors!
likely!contribute!although!the!exact!pathologic!basis!for!the!necrotizing!hemorrhagic!
features!of!USA300!remains!unclear.!!!
Panton-Valentine leukocidin (PVL), is a virulence factor which has!received!much!
research!attention, and is expressed by a large number of USA300 isolates, and by
relatively few other MRSA or MSSA strains.8,9 PVL is a pore-forming toxin shown to cause
apoptosis of neutrophils in low doses and neutrophil necrosis in high doses, which may
provide an explanation for the paucity of neutrophils seen histologically in USA300 affected
lungs.9,10 It is unlikely, however, to be the sole mediator, as similar pathologic lesions are
described post-infection with USA300 strains not expressing PVL, and other virulence
factors including phenol soluble modulins (PSMs) and the super antigen Selx have been
shown experimentally to induce similar lesions.11,12!
!

S.!aureus!pneumonia!has!an!acute!clinical!course!in!naturally!occurring!human!

infections!and!animal!models.13!!As!such!innate!immune!defenses!generated!at!early!

!
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time!points!are!critical!for!bacterial!clearance!and!host!survival.!!!In!addition!to!soluble!
mediators!such!as!complement,!collectins!and!ficolins,!S.!aureus!interacts!with!
pulmonary!epithelial!cells!and!macrophages!via!pattern!recognition!receptors!(PRRs)!
such!as!TLR2,!NOD2,!and!NLRP3,!initiating!proIinflammatory!signaling!cascades!which!
upregulate!expression!of!genes!important!for!host!defense!and!leukocyte!recruitment.
While undoubtedly some degree of pro-inflammatory signaling is necessary for bacterial
clearance and neutrophil recruitment, it remains unclear which signaling cascades are vital,
dispensable, or actually counter productive for protective immunity. Interestingly while mice
deficient in the TLR2 adaptor protein MYD88 are highly susceptible to systemic infection
with S. aureus, these mice are able to control pulmonary infection with maintained
cytokine/chemokine and neutrophil responses.14 In contrast NOD2-/- mice challenged intratracheally with S. aureus do have diminished cytokine/chemokine responses and neutrophil
influx, however, reduced inflammatory signaling in this model lead to improved bacterial
clearance.15 !
Despite its role in neutrophil chemotaxis and ability to augment neutrophil and
macrophage mediated microbe killing, TNF-α levels were inversely correlated with outcome
in one study, while in another publication mice deficient in TNFR1, the TNF-α receptor,
cleared S. aureus more efficiently than wild type mice.13,16 Similarly there is an ill-defined
tipping point at which a robust neutrophilic response transitions from protective to
deleterious. Left unchecked, neutrophils can impart as much harm to the surrounding tissue
as to the pathogen via toxic mediators such as elastase, collagenase, and free radicals.1!
Ultimately the factors delineating what constitutes a protective versus harmful immune
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response to S. aureus continue to be elusive, warranting further studies into the pulmonary
innate immune response to this important pathogen.
Monocyte chemoattractant protein one (MCP-1) is a chemokine principally described
as a monocyte chemattractant, but has also been shown to recruit neutrophils to the airways
at early time points in E. coli and K. pneumoniae infection models, leading to generation of a
robust and protective neutrophilic response.17,18 MCP-1 is constitutively produced in the
lung, but production in epithelial cells and alveolar macrophages can also be upregulated
downstream of pattern recognition receptor or inflammatory cytokine signaling mediated by
substance including LPS and TNF-α.19 In a Pseudomonas aeruginosa pneumonia model,
immunohistochemistry demonstrated strong labeling of intracytoplasmic MCP-1 in murine
alveolar epithelial cells and alveolar macrophages post-infection.20
Secreted MCP-1 binds to its principal receptor CC chemokine receptor 2 (CCR2)
present on a variety of cells including monocytes/macrophages, fibroblasts, epithelial and
endothelial cells.19 CCR2 is a G-protein coupled receptor which is also integrated with
JAK/STAT signaling cascades.21,22 While receptor signaling allows for mobilization of
intracellular calcium stores necessary for polymerization of cytoskeletal components and
chemotaxis, the cascades initiated on CCR2 binding can be multiple and diverse, with other
important functions.21,22 For example, pulmonary epithelial cells stimulated with MCP-1 can
upregulate mucus production, MCP-1 is up-regulated in atherosclerotic lesions, MCP-1
levels correlate with progressive organ fibrosis in some models, and MCP-1 promotes
angiongenesis and macrophage infiltration in gastric carcinoma.23-26
Anti-MCP-1 therapies including MCP-1 blocking antibodies and gene therapy have
been developed to moderate chronic or deleterious inflammatory responses, fibrosis,
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angiongenesis, and tumor burden. To date parenteral administration of anti-MCP-1 or MCP-1
gene therapy have been utilized in a number of animal trials which collectively have
produced many promising results including decreasing intimal proliferation in
artheriosclerotic plaques, reducing vessel restenosis post-angioplasty, decreasing organ
fibrosis, and reducing overall tumor burden and angiongenesis in cancer models.24-27 As these
therapies progress towards human clinical trials, understanding the role of MCP-1 in innate
immune defenses and delineating important risk factors for patients receiving such treatments
becomes a priority; especially within the context of a hospitalized population, where S.
aureus infection is a common cause of comorbidity.
For these reasons we wanted to investigate the role of MCP-1 in pulmonary innate
immune responses in S. aureus pneumonia and hypothesized that MCP-1 would impart a
protective response. C57Bl/6, MCP-1-/- and MCP-1 AB blocked mice were infected intratracheally with S. aureus strain USA300 followed by analysis of local and disseminated
bacterial burden, pro-inflammatory cytokine, chemokine and pulmonary leukocyte
recruitment profiles, and lung histopathology.
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CHAPTER 2
THE ROLE OF NOD-LIKE-RECEPTORS IN THE PULMONARY SYSTEM
2.1. Abstract
Innate immunity is the first line of defense against microbes and as such innate
responses to infectious stimuli frequently dictate outcomes including survival. Whereas Tolllike receptors have been extensively studied and their importance in pathogen detection and
clearance well documented, the importance of NOD-like receptor (NLR) family members is
emerging. The lung contains resident immune cells such as leukocytes and epithelial cells
and is physiologically positioned to have constant and close contact with inhaled irritants and
invading microbial pathogens. As bacterial lung infections are a significant cause of worldwide mortality and innate immune responses often dictate survival from lung infections,
understanding the role of NLRs in the pulmonary system is of particular importance. This
review highlights recent advances in our understanding of NLR family members, with
specific focus on how these proteins sense and respond to pathogens and host-derived
substances during respiratory bacterial infections.
2.2. Introduction
The respiratory tract provides a unique microenvironment in which to explore the
complex interplay between host immune responses and exogenous stressors such as microbes
and environmental irritants is manifest. To be effective, respiratory immune responses must
be sensitive, rapid, and diverse; these requirements are driven by constant contact with both
commensal and pathogenic microbes and inhaled irritants such as smoke (e.g cigarette,
biomass burning) that may possess immuno-modulatory properties. Globally, bacterial
pneumonia represents an enormous burden of illness and is associated with substantial
morbidity and mortality and the expenditure of significant economic resources. In the last
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decade, the role of specific innate immune proteins in protecting the lungs from devastating
infections such as bacterial pneumonia has been widely investigated. The availability of
resources including specific gene-deficient mice has been a major driving force in this effort.
However, the regulation of immune responses during bacterial infection that eventually
contribute to host resistance has not been fully delineated. In this review, we focus on recent
advances in understanding the importance of NOD-like receptors (NLRs) in orchestrating the
innate immune response to bacterial infection.
2.3. Bacterial pneumonia
Pneumonia is an infection of lung parenchyma, usually with bacteria. Bacterial
pneumonia is common; in the United States, the incidence of bacterial pneumonia is 4
million adults per year. Moreover, bacterial pneumonia is responsible for significant
morbidity and mortality, accounting for 1.1 million hospitalizations, and 50,000 deaths per
year.28 In fact, despite treatment with antibiotics and supportive measures, bacterial
pneumonia remains the most common infectious cause of death in the U.S. Bacterial
pneumonia is characterized clinically by the acute onset of productive cough, fever, and
shortness of breath. Severe cases may progress to sepsis and respiratory failure requiring
mechanical ventilation. The diagnosis is confirmed by radiographic imaging.
Although the lungs are constantly exposed to inhaled pathogens, a sophisticated host
defense system is usually highly effective in the killing and clearance of microorganisms. In
the event of exposure to a high burden or high virulence of pathogens or in the setting of a
susceptible host, clinical pneumonia can develop. Certain bacteria have developed
sophisticated virulence factors to evade a normal host defense system; host characteristics
such as underlying structural lung disease, advanced age, and immunocompromised states

!
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such as HIV, chemotherapy, and chronic steroid use predispose to pneumonia. The most
common pathogens responsible for bacterial pneumonia are Streptococcus pneumoniae,
Haemophilus influenzae, group A streptococci, Moraxella catarrhalis, Staphylococcus
aureus, anaerobes, and aerobic Gram-negative enteric bacilli such as Escherichia coli,
Legionella spp., Mycoplasma pneumoniae, and Chlamydophila pneumoniae.
In response to bacterial infection, sentinel cells such as macrophages become
activated and secrete chemokines, which induce neutrophil migration into the lungs.
Neutrophils clear bacteria by phagocytosis followed by killing via proteases and reactive
oxygen species. Both the activation of sentinel cells and the phagocytosis and killing by
neutrophils are critically dependent on the recognition of pathogens by the innate immune
system.29
2.4. Host defense
The innate immune response, the first line of defense against invading pathogens, is
initiated when pattern recognition receptors (PRRs) on the surface or in the cytosol of
sentinel immune cells sense pathogen-associated molecular patterns (PAMPs) in their
vicinity. Following the interaction of PAMPs with PRRs, downstream signaling cascades are
activated leading to increased production of cytokines and chemokines that promote
recruitment of professional phagocytes and antigen-presenting cells to the site of infection
and/or tissue injury. Four major groups of PRRs have been identified: Toll-like receptors
(TLRs), Nucleotide recognition domain (NOD)-like receptors (NLRs), RIG (retinoic acid
inducible gene)-1-like receptors (RLRs) and lectin receptors. The PAMP ligands for specific
PRRs are highly conserved “non-self” molecular motifs of microbial origin; examples
include lipopolysaccharide (LPS), peptidoglycan (PGN), flagellin, and CpG nucleotides. As
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these motifs are common to both pathogenic and commensal microbes, PAMPs may be
regarded as a misnomer for which a more inclusive acronym MAMP (microbe-associated
molecular patterns) has been proposed.30 PRRs can also interact with another set of
molecular motifs known as damage (or danger) associated molecular patterns which are
endogenous (“self”) molecules emanating from stressed (dying/infected/neoplastic) cells.
2.5. The NLR family
The NLR family consists of 22 members in humans, with protein orthologs in both
vertebrates and invertebrates.31 NLRs are critical to the innate immune response. Unlike the
transmembrane TLRs that detect either extracellular or endosomal ligands, NLRs exclusively
sense cytosolic ligands.32 All NLR family members are characterized by a tripartite domain
structure with C terminal leucine rich repeat (LRR) domain, a central NACHT (NAIP, CIIA,
HET-E, TP1) /NOD domain and a variable N-terminal effector domain.33 NLRs are classified
into 4 sub-families based on the N-terminal effector domain they contain: NLRA members
have transactivator domains (AD); NLRBs have BIR (baculoviral inhibitor of apoptosis
repeat) domains; NLRCs have CARD (caspase activation/ recruitment domains), and NLRPs
have PYD (PYRIN domains) 31,34 (Figure 1). Each domain of the NLR molecule has a unique
function. The C terminal LRR sensing domain recognizes and binds to a variety of cytosolic
ligands. This is followed by oligomerization of NACHT domains, a crucial but incompletely
understood step. Oligomerization leads to the formation of an N-terminal platform where
diverse adaptor molecules and downstream effectors may bind.31,34 The variable molecular
makeup at the N terminus ascribes a degree of structural heterogeneity that is utilized during
activation of diverse signaling pathways depending on the specificity of NLR and/or their
ligands (Figure 2).
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Figure 1. A schematic comparing molecular structures of different NLR family members. All
NLR family members have a tri-partite domain organization comprising of C-terminal LRR,
middle NACHT and a variable N-terminal domain. The variability of N-terminal domains is
the basis for the division of NLRs into distinct subgroups.
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Figure 2. A schematic representation of NLR signaling pathways. Various PAMPs ligands
that bind cytosolic NLRs and activate downstream pro-inflammatory signaling pathways in
the respiratory tract are indicated.
The NLR ligands range from bacterial and viral components to particulate matter and
crystals. For intracellular pathogens and pathogens equipped with trans-membrane secretion
systems (e.g., the type III secretion system of Pseudomonas aeruginosa and Dot/Icm type IV
secretion system of Legionella pneumophila (Lp) 35,36), the PAMPs are delivered to the
cytosol. Recent work demonstrates that extracellular Gram-negative bacteria can shed outer
membrane vacuoles or “blebs” containing bacterial products that can be transported by lipid
rafts to the cytosol of non-phagocytic cells for interaction with the NOD1 NLRs.37 Apart

!
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from these examples, the exact molecular mechanism(s) for transport of the majority of NLR
ligands across the host cell membrane remains elusive.
2.6. NOD1/NOD2 signaling
The cytosolic proteins NOD1 and NOD2 contain CARD domains at their N-termini.
While NOD1 is expressed in a wide variety of cells and tissues, NOD2 is expressed in
relatively few cell types including macrophages, dendritic cells, keratinocytes, and lung and
intestinal epithelium.31 Principally described ligands for NOD receptors are components of
bacterial peptidoglycan. Specifically, m-DAP (L-Ala-γ -D-Glu-m-diaminopimelic acid)
found in most Gram-negative and some Gram-positive bacteria binds NOD1while the MDP
(muramyl dipeptide) motif present in the peptidoglycans of both Gram-positive and Gramnegative bacteria binds NOD2 LRR.31 Peptidoglycan binding is followed by oligomerization
of the central NACHT domains and recruitment of the cytosolic adaptor molecule receptor
interacting protein 2 (RIP2 at the N-terminus by CARD-CARD interaction. RIP2 is then
ubiquitinated, leading to the activation of downstream NF-κB signaling and upregulation of
genes involved in host defense and apoptosis (Figure 2).15,31,38,39 In certain infection models,
membrane localization of the NOD-RIP2 complex is a prerequisite for activation of NF-κB
signaling 40 For example, the respiratory syncytial virus (RSV) induces the NOD2-RIP2
complex to bind the adaptor MAVS (mitochondrial viral signaling) on the mitochondrial
membrane 41, while the Shigella flexneri induced the NOD1-RIP2 complex to bind to the
host plasma membrane.40
2.7. Role of NOD receptors in bacterial pneumonia
The importance of NOD receptors in pulmonary defense is highlighted by studies
using murine models of bacterial pneumonia. In comparison with their WT counterparts,
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mice deficient in specific NOD receptors (NOD1-/- or NOD2-/-) or RIP2 (RIP2-/- , which are
functionally equivalent to NOD1-/-/NOD2-/- double knockouts) consistently show reduced
levels of pulmonary cytokines and chemokines accompanied by reduced inflammation and
impaired neutrophil recruitment to the lungs following infection with Escherichia coli 38,
Staphylococcus aureus 15 or Chlamydophila pneumoniae 39. In contrast, results from
pulmonary bacterial burden assays are not as consistent. NOD2-/- mice exhibit reduced
neutrophil killing and hence increased bacterial burdens following infection with E. coli. 38
Similar results (impaired cytokine/chemokine expression, delayed neutrophil recruitment and
bacterial clearance) are observed when RIP2-/- , NOD1-/-, and NOD2-/- deficient mice are
infected with C. pneumonia. 39 Surprisingly, in NOD2-/- mice infected with S. aureus,
reduced pulmonary neutrophils counts are accompanied by reduced bacterial CFUs.15
Similarly, in murine models of Legionella pneumonia, NOD1-/-, NOD2-/- and RIP2-/- mice
show impaired neutrophil recruitment compared to WT mice, although a small increase in
bacterial CFUs was observed only in the lungs of RIP2-/-mice.35 These results suggest a
possible co-operation between NOD1 and NOD 2 receptors in mediating Legionella-induced
activation of RIP2. Taken together, these observations firmly establish NOD receptors at the
crossroads of bacterial PAMP identification, pro-inflammatory pathways and neutrophil
recruitment. Their importance in resolution of infection by promoting bacterial clearance
varies with specific pathogens.
In addition to the well-documented role of NOD receptors in neutrophil recruitment,
NOD1/NOD2 signaling also contributes to the production of soluble anti-bacterial and antiviral molecules. Synthetic PAMPs have been shown to induce human oropharyngeal
epithelial cells to produce the antibacterial molecule β-defensin 2 in an NF-κB dependent
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manner in vitro.42 NOD2 is also involved in induction of type I interferon (IFN) in response
to intraphagosomal Mycobacterium tuberculosis in murine macrophages 43 and also in
response to RSV ssRNA, a non-peptidoglycan PAMP.41
2.8. NLR inflammasomes
Upon ligand binding, NLR proteins NLRC4, NLRP1, and NLRP3 form distinct
hetero-oligomeric structures known as inflammasomes, which are platforms for the
recruitment of pro-caspase1 zymogen by CARD-CARD interaction followed by activation by
proteolytic cleavage. Caspase 1 protease in turn activates pro-IL1β and pro-IL-18 to IL1β
and IL-18 respectively inducing inflammation and/or cell death, a process termed
‘pyroptosis’. The CARD in an inflammasome may belong to either a constituent NLR such
as NLRC4 (NLR family, CARD domain containing 4), or alternatively, to a CARD
containing adaptor protein ASC (apoptosis-associated speck like protein containing a CARD
1) recruited by a homotypic PYD interaction between ASC and NLRP1 or NLRP3.34,44 The
molecular components of different inflammasomes, downstream signaling cascades, and
their relevance to bacterial pneumonia will be discussed below.
2.9. NLRC4 and NAIPs
NLRC4 and NAIP (NLR family apoptosis inducing protein) are two structurally
dissimilar NLR proteins that form inflammasomes following activation by two bacterial
PAMP ligands, flagellin, and the type III secretion system needle apparatus constituent
protein PrgJ.44,45 Similar to NOD1/NOD2, NLRC4 consists of an N terminal CARD (Figure
1), although oligomerization of the central NACHT/NOD domains by NLRC4 proteins
results in the formation of an inflammasome (Figure 2).44 The concept of the NAIP-NLRC4
inflammasome originates in observations that the macrophages from A/J mice are highly
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permissive to Legionella replication in comparison to macrophages from other mouse strains
such as C57BL/6, Balb/C and C3H/HeN.46 This phenotypic difference was subsequently
mapped to the presence of a chromosome 13 locus containing a family of Naip (neuronal
apoptotic inhibitory protein) genes in non-permissive mouse strains.44,46 Today we know that
there are four Naip paralogs in mice (i. e. Naip1, Naip2, Naip5, and Naip6), while only one
functional protein, NAIP, has been detected in humans.44,47 Polymorphism of the Naip5 gene
in A/J mice has been implicated in their relative susceptibility to Legionella, based on the
observation that Naip5-/- mice in a C57/BL6 background are highly susceptible to Lp.48
Similarly, the replication of Lp in human macrophages which precedes the development of
Legionarre’s disease in people, is likely explained by the lack of human Naip to respond to
bacterial flagellin.45
Naips exhibit tripartite protein structure with C-terminal LRR, middle NBD and Nterminal BIR domain akin to other NLR family members. Three tandem repeats of BIR at the
N-terminus is a feature that Naips share with members of the apoptosis inhibitory protein
(AIP) family (Figure 1), although most experimental evidence indicates that the primary role
of Naips is in the regulation of innate immunity rather than apoptosis.44 Naip5 and NLRC4
functionally complement one another as inflammasome constituents with Naip-LRR acting
as a PAMP sensor while NLRC4-CARD recruits and activates pro-casapse1 by CARDCARD interaction. The role of the BIR domains in the organization of inflammasomes, their
downstream signaling and their relevance to immune defense against bacterial pathogens
remains to be elucidated, although it is proposed that all three BIR domains are necessary for
PAMP-induced oligomerization of NLRC4.49
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In the case of Legionella, murine Naip5 and human NAIP act as cytosolic sensors that
oligomerize with NLRC4 in response to flagellin. While the molecular mechanism leading to
inflammasome assembly remains nebulous, the NLRC4-Naip interaction has been fairly
well-defined.44 In contrast, the concept of NLRC4-Naip functional complementarity is wellestablished. As Naip5 lacks CARD, it is structurally incapable of recruiting and activating
caspase1 by itself. Thus NLRC4-/- mice are defective in mounting an inflammaory response
to cytosolic flagellin from Salmonella typhimurium.44,50 Also, macrophages from Naip5-/mice fail to activate caspase-1 and IL-1β and do not undergo pyroptotic death in response to
Legionella.48 Additional biochemical evidence further strengthens this concept: constitutively
active NAIP5ΔLRR induces oligomerization of NLRC4, a step necessary for production of
Caspase-1 even in the absence of flagellin ligand, while constitutively active NLRC4ΔLRR
activates caspase-1 even in absence of NAIP5.49 The dispensability of Naip5, as observed in
certain models of NLRC4 inflammasome activation, spearheaded the investigation of other
Naips as potential cytosolic sensors involved in ligand binding. Naip paralogs are proposed
to be involved in differential ligand recognition. For example, Naip5 LRR (and to some
extent Naip6 LRR) selectively recognizes flagellin, Naip2 LRR recognizes PrgJ (T3SS
needle protein) while Naip1 is an orphan member with an unknown PAMP ligand.45,49
These observations clearly establish Naips as cytosolic sensors of different PAMPs that act
upstream of NLRC4 effectors.
A recent publication has documented that both murine and human macrophages
respond to Klebsiella pneumoniae via NLRC4 activation, and that NLRC4 activation is
critical for development of protective immunity in a murine in vivo model.51 Further studies
are needed to determine the importance of NLRC4 in innate immune responses to other
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relevant pulmonary pathogens, including both murine models and human cell lines, given the
dissimilarities present in NAIP expression between mice and humans.
Since NLRC4 is equipped with its own CARD domain, whether the ASC adaptor is
necessary for NLRC4 inflammasome function is not fully established 44. Legionella activates
two independent pathways of caspase1 activation via induction of ASC or NLRC4-NAIP
inflammasomes.52 Ligands and upstream effectors of ASC-dependent pathway are unknown.
Activation of both pathways is required for maximal production of IL1β and IL18 although
NLRC4-NAIP-mediated pyroptosis is independent of ASC activity.52 Based on more recent
microscopic evidence, ASC appears to be involved in spatial sequestration of NLRC4 caspase1 complexes.53 This suggests convergence of these two pathways at a centralized
ASC platform which may help in maintaining a delicate balance between two caspase 1induced downstream processes; pyroptosis and proinflammatory cytokine release.
2.10. NLRP1
NLRP1 is structurally distinct from other NLRs in that it has two signal transduction
domains; PYD at the N-terminus and CARD at the C-terminus. The LRR domain is
positioned between PYD and the central NOD (Figure 1). It is proposed that the C-terminal
CARD binds caspase 5 while the N-terminal PYD homotypically binds PYD of ASC. ASC is
a bipartite adaptor that in turn contributes CARD for recruitment and induction of pro
caspase-1.34,54 The NLRP1 inflammasome platform composed of CARD8, ASC, caspase-5,
and caspase-1 was first described in a cell-free system.34,55 It has been suggested that the
activities of both caspase 1 and 5 are necessary for NLRP1 inflammasome mediated IL1β
maturation.34,55 Biochemical evidence suggests that NLRP1 inflammasome activation is a
two-step process. In the first step, bacterial MDP PAMP binds NLRP1 LRR and primes the
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central NACHT domain for NTP binding leading to the second step of NLRP1
oligomerization and procaspase-1 recruitment. ASC may augment the function of NLRP1 but
is not required for inflammasome function, as NLRP1 equipped with C-terminal CARD may
interact with procaspase-1 bypassing the requirement of ASC.34,56
Unlike humans with a single functional nlrp1 gene, the murine genome encodes three
highly homologous, tandem paralogs; nrlp1a, nlrp1b, nlrp1c. Nlrp1b is a highly polymorphic
paralog that is activated by proteolytic cleavage mediated by Bacillus anthracis virulence
factor, anthrax lethal toxin.57 This leads to caspase1 activation which is the molecular event
that determines strain-specific susceptibility of murine macrophages to anthrax lethal
toxin.34,58 Activation of NLRP1 by anthrax lethal toxin has been shown to result in
irreversible acute lung injury that is dependent on caspase1 activation and not on IL1β
maturation. In contrast, the ligand for highly conserved NLRP1a is undefined 59, while the
NLRP1c is a truncated protein with unknown relevance to inflammasome assembly/function.
Notably, anthrax lethal toxin does not activate human NLRP1. Although the role of NLRP1
in human health and disease remains elusive, the interaction of murine NLRP1 and LT
illustrates that NLR activation can be responsible for significant end organ damage.
2.11. NLRP3
The defining feature of NLRP3 (NLR family; PYD containing 3) is the N terminal
PYD (Figure 1) that homotypically binds PYD of ASC. The NLRP3 inflammasome is
prototypical in its requirement for two distinct signals for activation. The pre-assembly
“priming” signal comes from TLR activation that induces NLRP3 expression via NF-κB
activation. Once the cytosolic amount of NLRP3 reaches a threshold, inflammasome
assembly is initiated in response to a second signal in the form of one or more of NLRP3
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ligands.60 The two signal process may act as a cellular safeguard against hyper-activation of
the NLRP3 inflammasome. NLRP3 ligands are a curiously heterogeneous group of
compounds ranging from exogenous materials such as bacterial PAMPs, ozone, asbestos,
silicon and particulate matter to endogenous alarmins such as uric acid from DNA damage,
ATP and mitochondrial contents.61-66 Hyperactivation of NLRP3 resulting in increased
accumulation of pro-inflammatory cytokines such as IL1β is involved in the pathogenesis of
pulmonary fibrosis.67,68 The ability of the NLRP3 inflammasome to respond to an array of
structurally and chemically diverse signals points to convergence on a common sub-cellular
signaling event upstream of inflammasome assembly. Presently, three signaling pathways
have been proposed to be involved in these processes: ROS (reactive oxygen species),
intracellular electrolyte shift (K+ efflux), and lysosomal disruption.69-71 Needless to say, each
of these models has limitations. ROS production may qualify as the common upstream
signaling effector based on the observations that ‘frustrated phagocytosis’ of large crystals
(e.g.; asbestos) activates mitochondrial NADPH oxidase (NOX) and that NLRP3
inflammasome assembly is affected by ROS inhibitors.65,72 Recently, Bauernfiend et al have
suggested that ROS activation is an important upstream event required for the priming of
NLRP3 inflammasome formation.69 Large crystal phagocytosis is also implicated in
lysosomal rupture, release of lysosomal protein cathepsin B in the cytosol and subsequent
activation of NLRP3 based on the observation that cathepsin B inhibitors abrogate crystalmediated NLRP3 inflammasome activation while artificial lysosomal disruption (mediated
by osmolarity alterations) activates NLRP3 inflammasome.71 ATP mediated potassium
efflux and calcium influx activates ion channel function of purinergic receptor P2X7 also
resulting in the activation of the NLRP3 inflammasome.70 Conversely, the presence of high

!
!

19

K+ containing buffers blocks NlRP3 inflammasomes.66 Pore formation by P2X7-activated
Pannexin or by the activity of microbial toxins activates the NLRP3 inflammasome.73
Bacterial pore-forming toxins (PFTs) such as streptolysin O (Streptococcus pyogenes), alphahemolysin (S. aureus), and hemolytic pneumolysin (ply, Streptococcus pneumoniae) are
particularly relevant virulence factors involved in the pathophysiology of bacterial
pneumonia and are established as inducers of NLRP3 inflammasomes.61-63,74,75 The
variability of PFT expression among bacterial strains in part dictates the immunologic
response generated. For instance S. pneumoniae strains producing non-hemolytic variants of
ply are capable of establishing infection without activating IL-1β production via NLRP3.62
Whether the membrane channels/pores induce K+ efflux or function as trans-membrane
gateways facilitating entry of ligands into the cytosol allowing for direct interaction with
NLRP3 is not clear.
What is apparent, is that NLRP3, through cross-talk with TLRs, and ability to
recognize diverse ligands, may play a crucial role in pulmonary immunity. The inflammation
resulting from NLRP3 activation may facilitate clearance of pneumococci producing
hemolytic pneumolysin, or it may abrogate replication of the atypical mycobacterial
pathogen M. kanasii in human macrophages.61,76 In other instances, such as asbestosis and
silicosis, NLRP3 activation is deleterious as it promotes chronic inflammation and fibrosis.72
Furthermore, its ability to sense and respond to endogenous alarmins that leak from necrotic
cells, indicates it could be activated downstream of any pulmonary condition that induces
necrosis.63
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2.12. NLRP6 and NLRP12
The newly recognized NLRP6 and NLRP12 are inflammasome-forming NLRs that
oligomerize with ASC, although details about the downstream signaling pathways are
lacking.77-80 However, in this context the term inflammasome may be a misnomer, as
NLRP6 and NLRP12 may induce anti-inflammatory immune responses. Detection of high
levels of nlrp6 transcripts in neutrophils, T cells, macrophages and epithelial cells 81 suggests
that NLRP6 may be relevant in the immune defense of respiratory tract and other organs.
NLRP6 -/- mice display reduced IL-18 levels and colonic dysbiosis (alteration in the structure
of normal intestinal microflora) leading to inflammatory colitis.77,78 NLRP6 is dispensable
for Listeria monocytogenes induced neutrophil IL-1β release.82 Moreover, in a mouse model
of infection with Listeria, NLRP6-/- mice have a survival advantage over their WT
counterparts and show increased levels of circulating levels of neutrophils and macrophages
accompanied by increased clearance of bacteria from liver and spleen. Whether NLRP6
suppresses innate immune function in response to other bacterial pathogens is unknown.83
NLRP12 is a prototypical member of anti-inflammatory NLRs; it is exclusively produced by
eosinophils, granulocytes and monocytes and it is an established negative regulator of the
non-canonical pathway of NF-κB activation.80,84 NLRP12 suppresses IL1β and IL18
production (and IFNγ production via IL18) mediated by Yersinia pestis 79 although no
differences were observed in survival profiles, disease progression, and host response
mounted by NLRP12 -/- and WT mice after airway exposure to M. tuberculosis or K.
pneumonia.85
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2.13. Perspective
With the rapidly expanding knowledge of innate immune responses at the molecular
level, a more comprehensive approach is needed to link seemingly unrelated molecular
effectors and parallel signaling pathways in relation to one another is urgent. This will not
only generate comprehensive maps of intricate molecular mechanisms of innate immune
responses to invading pathogens, but identifynovel targets for future therapeutic
interventions. Discovery of inflammasomes, and the description of crosstalk between TLRs
and NLRs to generate proinflammatory cytoking responses, represent the initial steps
towards a more complete understanding 86 It is evident that the specificity between
interacting PRRs and PAMP ligands is not exclusive, and that activation of a particular PRR
may lead to the simultaneous induction of different signaling pathways.87 Despite these
major discoveries , many crucial questions remain unanswered, including 1) What are the
PAMP ligands activating inflammasomes such as NLRP4 and NLRC4?; 2) How are the
molecular patterns of extracellular pathogens transported across the cytoplasmic membrane?;
3) What factors determine whether activation of inflammasome pathways result in an
inflammatory response or cell death? A better understanding of interplay between different
PRRs in response to a pathogenic insult will pave the way for more sophisticated therapies
for a number of infectious, autoimmune, and neoplastic diseases in the lung and other organs.
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CHAPTER 3
LITERATURE REVIEW
3.1. Innate immunity in bacterial pneumonia
Innate immunity is the body’s first line defense system, and consists of molecular
sensors and effectors that are activated in response to invading pathogens or endogenous
signals. Cellular components of innate immunity include surface epithelium and leukocytes
such as histiocytes (macrophages and dendritic cells), neutrophils, natural killer cells, mast
cells, eosinophils and basophils. A wide array of intracellular and extracellular proteins
assist in innate immunity including soluble and cell associated pattern recognition receptors,
enzymes capable of hydrolyzing cell wall components or creating toxic oxygen/nitrogen
compounds, as well as constituents of the complement cascade and acute phase response.22
The ways in which cells sense invading microbes, the signaling cascades which occur
downstream of pathogen recognition, and the antimicrobial properties of various innate
immune effectors are outlined below, with particular focus on those central to bacterial
clearance in pneumonia.
3.1.1. Cellular effectors
3.1.1.a. Neutrophils
Neutrophils are short-lived bone marrow derived granulocytic cells that provide the
first line of defense against many invading microbes. Neutrophils are professional
phagocytic cells that contain granules replete with bactericidal substances. The
primary/azurophilic granules in neutrophils contain myeloperoxidase (MPO), other
proteolytic enzymes (cathepsins, elastase), and defensins.1 Secondary/specific granules, so
called as they develop second in neutrophil maturation, contain important membrane proteins
including lactoferrin and collagenase as well as receptors for chemotactic molecules,
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cytokines, opsonins, and extracellular matrix proteins. In health, murine neutrophils circulate
for 10-24hrs before entering tissues where senescent neutrophils become apoptotic and are
engulfed by macrophages.1 During inflammation, microbe and host-derived signals initiate
immune cascades resulting in production of neutrophil chemotactic molecules (i.e. IL-8, GCSF) which can bind to receptors on neutrophils initiating chemotaxis towards sites of
inflammation, while altering expression of integrins on endothelial cells to promote
neutrophil extravasation into tissues.
Neutrophils are equipped with cell associated pattern recognition receptors (PRRs)
including Toll-like receptors (TLRs) and Nod-like receptors (NLRs). PRRs recognize highly
conserved motifs of pathogens, known as pathogen associated molecular patterns (PAMPs)
as well as substances (i.e. mitochondrial DNA, heat shock proteins) liberated from stressed or
dying host cells, known as danger associated molecular patterns (DAMPs). Activation of the
cell-associated PRRs by PAMPs/DAMPs in neutrophils initiates intracellular signaling
cascades resulting in neutrophil phagocytosis, degranulation, reactive oxygen species
production, and cytokine/chemokine generation.1 Additionally neutrophils have receptors for
soluble PRRs such as collectins, as well as complement, both of which enhance phagocytosis
of bacteria via opsonization.
Once bacteria are inside neutrophil phagosomes, the contents of primary and
secondary granules can fuse with the phagosome, exposing organisms to bactericidal
products including oxygen dependent (i.e. ROS, superoxide, MPO) and independent (i.e antimicrobial peptides, elastase, lactoferrin) substances.1 A more recently identified means of
neutrophil-mediated microbe killing is via formation of neutrophil extracellular traps (NETs).
NETs are comprised of chromatin, histones, azurophilic granules and cytosolic proteins with
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bactericidal activity demonstrated against a variety of pathogens including S. aureus. It
appears that generation of ROS is a prerequisite in some experimental models for NET
formation, however whether NETs constitute a unique form of cell death, or are cast from
live cells is still an issue of debate.1
Neutrophil apoptosis is a form of anti-inflammatory cell death that occurs both in
healthy cells as a natural regulator of neutrophil numbers, and in states of
inflammation/infection. While the mechanisms governing neutrophil apoptosis differ in
health and disease, the net result is caspase-mediated cleavage of nuclear contents,
preservation of the cell membrane (preventing liberation of highly inflammatory neutrophil
products into the extracellular space) and exposure of phosphatidylserine (PS) onto the
extracellular lipid bilayer. PS acts as a signal for macrophages to engulf these senescent cells
(efferocytosis). In addition to freeing the extracellular space of the many toxic products
present within neutrophils, the action of efferocytosis by macrophages causes these
professional phagocytes to produce the anti-inflammatory cytokines IL-10 and TGF-β,
further contributing to resolution of inflammation.1
3.1.1.b. Alveolar macrophages
Alveolar macrophages (AMs) are specialized macrophages that reside in the alveoli.
Studies support both monocyte and pulmonary derived sources of AMs. Studies in mice
estimate 15% of blood monocytes migrate to the lungs to replace AMs. However maturation
of AMs from pulmonary cells of intermediate differentiation has also been demonstrated.13
Alveolar macrophages respond to invading pathogens by both phagocytosis and immune
signaling via PRRs. Phagocytosis is mediated by binding of opsonized or non-opsonized
microbes to a plethora of receptors. Within macrophages nitric oxide is produced via
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inducible nitric oxide synthase. Theorized to perhaps protect the lung tissue in their
surrounding specialized micro-environment, AMs in humans produce NO to a lesser extent
than inflammatory macrophages in other tissues and also have efficient anti-oxidant
mechanisms.13 While these cells are professional phagocytes, their ability to ingest
pathogens is ultimately limited. In addition to phagocytosis, sensing of microbial PAMPs by
AMs occurs via PRRs (TLRs and NLRs). These signaling cascades not only enhance
microbe killing and phagocytosis by AMs but also recruit neutrophils to the airways.
3.1.1.c. Epithelial cells
A heterogenous population of epithelial cells exists from the trachea to the alveoli
including basal cells, secretory and ciliated epithelial cells, neuroendocrine cells and type I
and type II alveolar pneumocytes.95 The production of mucus and movement of cilia serve to
trap inhaled irritants and microbes and propel them back towards the oropharynx. Surfactant
proteins A and D produced by type II alveolar pneumocytes are anti-bacterial collectins.13 In
addition to these constitutive anti-bacterial functions, epithelial cells are able to initiate
immune responses via pathogen sensing and subsequent pro-inflammatory signaling
cascades. As previously mentioned, NFκ-B is an important transcription factor in proinflammatory signaling. In pneumonia models where NFκ-B was selectively blocked in
alveolar epithelial cells, generation of cytokines and chemokines and degree of inflammatory
cell infiltrate after pathogen challenge were severely blunted.13 In separate experiments
using mice deficient in the TLR adaptor MYD88, it was shown that the NF-κB mediated
signaling was reestablished after selectively restoring MyD88 function to alveolar epithelial
cells, suggesting TLRs are central to NFκ-B cascades generated in epithleial cells.13

!
!

26

Another transcription factor important in epithelial cell response in pneumonia is
STAT3. Unlike NFκ-B, STAT3 activation does not appear to occur via PAMP/PRR
interactions on epithelial cells, but rather via cross talk between epithelial cells and resident
leukocytes. The importance of STAT3 in pulmonary immunity is obvious in the naturally
occurring human disorder hyperimmunoglobulin E syndrome (HIES) in which patients have
severely decreased levels of STAT3. While all cells in the body are deficient in STAT3
expression, the clinical course of this disease is typified by recurrent pulmonary infections,
often beginning early in childhood, with pneumonia being the major cause of death in these
patients.13 Increased susceptibility to pneumonia in these patients may involve epithelial
cells directly and indirectly. STAT3 is activated downstream of IL-6 and IL-23 and is vital
in differentiation of TH17 T cells. TH17 cytokines (IL-17, IL-22) play important roles in
pulmonary immunity, some of which is achieved via signaling with epithelial cells and
inducing these cells to produce β-defensins and CXC chemokines.13 However, selectively
blocking STAT3 in T cells fails to recapitulate the HIES phenotype.13 When STAT3 was
selectively blocked in the alveolar epithelial cells of mice, animals had more severe lung
injury as compared to WT controls, the degree of which did not correlate with neutrophil
recruitment between the groups, suggesting a role for STAT3 in maintaining epithelial cell
health independent of inflammatory signaling.13
3.1.2. Pattern recognition receptors
Pattern recognition receptors (PRRs) are cell associated or secreted molecules that
recognize “non-self” signals known as pathogen-associated molecular patterns (PAMPs)
including bacterial and viral components or endogenous danger associated molecular patterns
(DAMPs) such as mitochondrial DNA and heat shock proteins liberated from dying cells.
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Some cell associated PRRs, including CD14 and C-type lectin receptors, are endocytic
receptors that initiate internalization and phagocytosis of pathogens upon PAMP binding.
Similarly soluble PRRs including collectins and ficolins opsonize pathogens, tagging them
for phagocytosis, and also aid in complement associated killing.14 In contrast the cell
associated Toll-like receptors (TLRs) and NOD-like receptors (NLRs) initiate intracellular
signaling cascades upon PAMP binding, which culminate in pro-inflammatory chemokine
and cytokine production, and in some instances, programmed cell death.
The TLR family includes unique transmembrane receptors expressed by a wide
variety of cells such as lymphocytes, histiocytes, epithelial cells, endothelial cells, and
fibroblasts, which vary slightly in number across mammalian species (i.e. 12 murine TLRs
and 10 human TLRs).13 Cell membrane associated TLRs (TLR 1,2,4,5,6) sense an array of
peptides and lipopeptides including bacterial cell wall components and flagellin, whereas
endosomal TLRs (3,7,9) sense nucleic acids.14 These receptors are comprised of PRR
sensing C terminal leucine rich repeats (LRR), a trasmembrane domain, and a N terminal toll
and interleukin receptor (TIR) which associates with downstream adaptor proteins (most
importantly MyD88) to initiate intracellular signaling. The TLR signaling cascade leads to
NFκ-B and MAP kinase activation culminating in increased production of inflammatory
cytokines such as TNF-α and IL-6 and neutrophil and monocyte chemotactic molecules such
as IL-8 and MCP-1 (Figure 3).14
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Figure!3.!Innate!immune!signaling.!!Signaling!cascades!initiated!by!S.!aureus!interaction!
with!TLR2!and!NLRs!(i.e.!NOD2,!NLRP3)!in!pulmonary!epithelial!cells.!!
NLRs similarly display tripartite structure with a C terminal leucine rich repeat
domain, a central NACHT (NAIP, CIIA, HET-E, TP133)/NOD domain and a variable Nterminal effector domain.31 The NLR ligands range from bacterial and viral components, to
particulate matter and crystals. For the well studied NLRs such as NOD1/NOD2, ligands
include components of bacterial peptidoglycan. Specifically, m-DAP (L-Ala-γ -D-Glu-mdiaminopimelic acid) found in most Gram-negative and some Gram positive bacteria, is
detected by NOD1while MDP (muramyl dipeptide) motif, ubiquitously present in the
peptidoglycans of both Gram-positive and Gram-negative bacteria, is detected by NOD2
LRR.31 PGN binding is followed by oligomerization of the central NACHT domains and
recruitment of the cytosolic adaptor molecule RIP2 (receptor interacting protein 2) at the Nterminus by CARD-CARD interaction. RIP2 is then ubiquitinated leading to the activation of
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downstream NF-κB signaling and upregulation of genes involved in host defense and
apoptosis (Figure 2).31
Upon ligand binding, some NLR proteins (NLRC4, NLRP1, and NLRP3) form
distinct hetero-oligomeric structures known as inflammasomes which are platforms for the
recruitmentof pro-caspase 1 zymogen followed by its activation to caspase 1 by proteolytic
cleavage. Caspase 1 protease in turn activates pro-IL1β and pro-IL-18 to IL-1β and IL-18
respectively, inducing inflammation and/or inflammatory cell death termed pyroptosis
(Figure 3).65 Of the inflammasomes NLRP3 arguably has the most relevance to pulmonary
pathology, as it is documented to respond to a curiously heterogenous group of compounds
ranging from exogenous materials such as bacterial PAMPs, ozone, asbestos, silica and
particulate matter to endogenous alarmins such as uric acid from DNA damage, ATP and
mitochondrial contents.65,75
3.1.3. Cytokines and chemokines
Cytokines are small soluble proteins secreted by immune (ie monocytes, dendritic
cells, granulocytes, lymphocytes) and non-immune cells (fibroblasts, epithelial and
endothelial cells). Cytokines can be broadly grouped into five families based on
functionality: interleukins, interferons, TNF ligands, growth factors, and chemokines. Major
cytokines and chemokines of interest at early time points in pulmonary innate immune
responses to bacterial pathogens are described below.
3.1.3.a. TNF-α
Part of the TNF super family, TNF-α is produced predominately by macrophages but
is made by a wide array of other cells including neutrophils, mast cells, endothelial cells,
fibroblasts, NK cells and CD4+ T cells in response to microbial products and cytokines such
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as Il-1, IL-2, and interferon.96,97 The cell associated form of TNF-α is released by the action
of ADAM 17 (also termed TNF-α converting enzyme) in a homotrimer form, necessary for
binding to its receptor.97 TNF-α induces endothelial cells to express neutrophil adhesion
molecules (ICAM-1 and VCAM-1), augments immune cell function such as macrophage
phagocytosis, cytokine secretion, release of reactive oxygen species, and provides positive
feed back for NFκ-B activation to increase levels of pro-inflammatory cytokines.96 It also
has distant effects that include crossing the blood brain barrier to interact with the
hypothalamus to induce fever, and causing hepatocytes to upregulate the production of acute
phase proteins such as protein C which enhances complement function.96
3.1.3.b. IL-6
IL-6 is produced primarily by monocytes and macrophages in response to signaling
via other cytokines (i.e. IL-1, TNF-α) or PAMPs (LPS, microbial nucleotides). IL-6 binds its
receptor (IL-6R) α chain and the signal transducing component gp130.97 It is the most
important signaling molecule for induction of the acute phase response. The acute phase
response refers to the modulation of protein synthesis, which occurs in the liver upon
stimulation with increased concentrations of cytokines such as IL-6, TNF-α and IL-1β.
During times of inflammation the liver down regulates production of albumin (the major
negative acute phase protein) presumably to use the amino acid precursors for formation of
positive acute phase proteins (APPs). There are many APPs with species specific relative
importance but ultimately, regardless of species, the concerted function of these proteins is to
enhance multiple facets of innate immunity including complement activation, opsonization,
scavenging of free radicals, protease inhibition, and coagulation.98 Additionally IL-6
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activates cytotoxic T cells and is involved in the differentiation of B cells into
immunoglobulin producing plasma cells.97
3.1.3.c. IL-1β and IL-18
IL-1β and IL-18 are both part of the IL-1 family. These cytokines are unique in that
they are synthesized in an inactive pro-enzyme form, requiring the activity of caspase-1
generated by inflammasome assembly to be cleaved into their active forms.97 IL-1β is
important in activating T-lymphocytes by enhancing production of IL-2 but also shares
biological functions with both TNF-α and IL-6 including upregulation of leukocyte adhesion
molecules (ie ICAM-1, VCAM-1, E-selectin) on endothelial cells, and mediating systemic
effects such as pyrexia and induction of the acute phase response. The final steps in ICAM-1
expression as mediated by IL-1 and TNF-α requires IL-18. Along with IL-12, IL-18 is also
an important inducer of INF-γ.97
3.1.3.d. IL-17
The IL-17 family is comprised of 6 members (IL-17A through IL17F) which share
virtually no sequence homology to other cytokines. IL-17A is often referred to
interchangeably as IL-17 and is primarily produced by a subset of CD4+ T cells (Th17 cells),
with other possible cellular sources including neutrophils, eosinophils and CD8+ T cells.97
Immune responses of IL-17A include induction of IL-6, IL-8, and granulocyte colony
stimulating factor (GM-CSF) in cellular targets (ie fibroblasts, endothelial cells, epithelial
cells) bearing the IL-17 receptor.97 Via its induction of IL-8 and G-CSF, IL-17 is an
important player in neutrophil recruitment to the airways, however its effect on pulmonary
immunity extend beyond leukocyte recruitment, as it can also induce goblet cell hyperplasia
and increase mucus production by pulmonary epithelium.97

!
!

32

3.1.3.e. IL-8
While initially termed as an interleukin, IL-8 is also referred to interchangeably as
CXCL-8, a more suitable nomenclature that denotes its major role as a chemokine, as well as
its structure. Chemokines are divided into four subclasses (CC, CXC, CX3, C) where C
denotes the arrangement of cysteines within the molecule.99 CXC chemokines such as
CXCL-8 have one intervening amino acid (ie X) between their cysteine residues. IL8/CXCL-8 is a potent neutrophil chemoattractant produced by many cell types (i.e.
leukocytes, endothelial cells, epithelial cells, fibroblasts) which binds to its receptors
(CXCR1 and CXCR2) to stimulate leukocyte transmigration, among other effects.99 CXCL8 is involved in removal of L-selectin and expression of integrins on neutrophils, and
facilitates transmigration of neutrophils across fibroblasts, endothelial and epithelial cells.
Additionally CXCL-8 induces many neutrophil mediated immune functions including
respiratory burst, degranulation, release of leukotriene B4 and synthesis of platelet activating
factor.99 It should be noted that both mice and rats, do not express CXCL-8, and its orthologs
responsible for neutrophil chemotaxis in these species include KC, MIP-2, and LIX.
3.2. Monocyte chemoattractant protein-1
Monocyte chemoattractant protein-1 (MCP-1) belongs to the chemokine family of
cytokines.100 Chemokines are small (8-10 kD) proteins primarily involved in leukocyte
trafficking during inflammation, infection, wound healing and in health. The term
chemokine is reserved for proteins with a conserved structure, and many potent
chemoattractants (C3a, C5a, leukotriene B4) are not classified as such. MCP-1 is a CC
chemokine, and is referred to interchangably as CC ligand 2 (CCL2) a pseudonym that
reflects its structure rather than functionality.100 All members of the CC chemokine group
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have the first two cysteines adjacent to each other while all members of CXC chemokine
group have one amino acid separating the cysteines.100 The structural similarity of
chemokines within subgroups allows for a certain degree of promiscuity in terms of
receptor/chemokine interaction. While chemokine receptor 2 (CCR2) is considered the main
receptor for MCP-1 (CCL2), human MCP-1 can also bind CCR1, CCR3, and CCR5.
Likewise CCR2 has other secondary ligands, including CCL7 and CCL12. 100,101
3.2.1. MCP-1/CCR2 signaling
Chemokines such as MCP-1 mediate their effects by binding to seven transmembrane
G protein coupled receptors (GPCRs) (Figure 4). The N terminus of the GPCR is present
extracellularly and is the site of ligand interaction. The intracellular C terminus interacts
with the alpha subunit of a trimeric G protein.100,102 The G protein subunits subsequently
dissociate and the alpha subunit is free to activate downstream effectors such as
phospholipase C (PLC). PLC catalyzes the formation of inositol triphosphate (IP3) and
diacyl-glycerol (DAG). IP3 can then open channels to release intracellular calcium into the
cytosol while DAG activates protein kinase C (PKC). PKC also mobilizes cellular calcium
stores.100 Increase in intracytosolic calcium is important for the ultimate function of
chemokine signaling, namely cell mobility. To move along the chemotactant gradient
requires the cell to move its cytoskeletal framework, a process dependent on polymerization
of the actin cytoskeleton and calcium/calmodulin interactions.100
Signaling through the GPCR may have other functions unrelated to mobility
(Figure 4).
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Figure!4.!General!schematic!of!a!CC!chemokine!binding!a!chemokine!receptor.!!
Chemokine!receptors!are!transmembrane!G!protein!coupled!receptors!but!are!also!
linked!to!JAK/STAT!signaling!pathways.!!Chemokine!binding!can!lead!to!activation!of!
multiple!downstream!signaling!cascades!resulting!in!cellular!motility!and!
transcriptional!activity!among!other!functions.!
For instance, PKC also plays important roles in polarization and adhesion, and is also
involved in the activation of transcription factor NF-κB mediated signaling reestablished
after selectively restoring MyD88 function to alveolar epithelial cells.100 G proteins can also
activate MAP kinases (p38 and ERK) which in turn activate a number of transcription factors
(CREB and c-jun).100 Additionally, chemokine receptors can directly recruit JAK proteins,
thereby allowing the activation of the JAK-STAT pathway, and subsequent STAT
dimerization and translocation to the nucleus to upregulate transcription of pro-inflammatory
cytokines.100 This paradigm proves true for murine macrophages that demonstrated tyrosine
phosphorylation of JAK2, STAT3 and STAT5 when cultured with MCP-1.21 JAK-STAT
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and GPCR pathways may in fact work in concert, as in some models where pharmacologic
inhibition or mutation of JAK caused defects in both JAK-STAT and GPCR signaling
cascades.103
The promiscuity of the chemokine ligand/receptor interaction and induction of
various intracellular cascades provides a high level of plasticity and intricacy to chemokine
signaling, which is further amplified by the finding that CCR2 has two isoforms (CCR2a,
CCR2b), and can also form heterodimers.104-106 Early experiments evaluating isoform
mRNA expression, and later work using isoform specific antibodies, support that CCR2b is
the predominant form expressed.105 CCR2b/CCR5 heterodimer formation has also been
found to occur in macrophages co-stimulated with the major ligands for these individual
receptors, MCP-1 and RANTES (regulated upon activation, normal T cell-expressed and
secreted) respectively, and shows preferential induction of leukocyte adhesion rather than
chemotaxis. 106
3.2.2. MCP-1 physiologic and pathophysiologic roles
Cellular sources of MCP-1 are diverse and include macrophages and dendritic cells,
endothelial cells, smooth muscle, fibroblasts, and some epithelial cells. CCR2 is expressed
on many of these same cell types such as macrophages and dendritic cells, endothelial and
some epithelial cells and fibroblasts, as well as on other immune cells including Tlymphocytes and neutrophils.107-17,108,109 Given the expression of CCR-2 by many MCP-1
producing cell types, studies have demonstrated autocrine feedback.108 While chemotaxis is
an obvious prerequisite for migration of inflammatory cells, it is also important to sessile cell
types. Stimulation with MCP-1 resulted in migration of endothelial cells as well as vessel
formation and migration of epithelial cells to cover denuded areas.107,109 Some of these cells
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constitutively produce MCP-1, production can also be upregulated or completely induced in
other cell types, with the same being true for CCR2 expression.20,108 Stimuli that induce
MCP-1 production or CCR2 expression vary with the cell type and model in question often
reflecting the underlying pathophysiology. For instance, in a model of vascular disease
MCP-1 production was induced by oxidized lipid and shear stress.110 However other known
MCP-1 inducers such as LPS, inflammatory cytokines (TNFα, IL-1) and a variety of TLR
agonists are more relevant within the context of infection models.19,111,112
3.2.2.a. The lung microenvironment
Pulmonary epithelial cells, alveolar macrophages, and endothelial cells are all
possible contributors as well as targets of MCP-1 within the lung. Both constitutive and
inducible expression of MCP-1 has been demonstrated in human bronchial epithelial cells
and alveolar macrophages (AMs) grown in vitro.19 In a model of bacterial pneumonia with
Pseudomonas aeruginosa, immunohistochemistry demonstrated strong labeling of
intracytoplasmic MCP-1 in murine alveolar epithelial cells 24 hours post infection, and in
both epithelial cells and alveolar macrophages by 48 hours post-infection. 20 In vitro work
also supports the expression of the CCR2 receptor on bronchiolar epithelial cells. Human
bronchiolar epithelial cell cultures incubated with MCP-1 were shown to upregulate both
mucus and MCP-1 production via the CCR2 receptor. 23 In addition to initiating protective
responses in the early phases of respiratory insult, interaction between MCP-1 and CCR-2
bearing epithelial cells and AMs may also contribute to healing via epithelial regeneration.
When incubated with MCP-1, alveolar epithelial cells from CCR2-/- mice or wild type mice
(WT) treated with MCP-1 antibody showed delayed mechanical wound closure compared to
WT controls.109 Additionally, in cell culture, MCP-1 causes murine AMs to increase the
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production of hepatocyte growth factor, a mitogen for bronchial and alveolar epithelial
cells.20
3.2.2.b. Bacterial pneumonia
To date the role of MCP-1/CCR2 has been investigated in a number of murine
pneumonia models using Gram-negative agents such as Escherichia coli, Klebsiella
pneumoniae, Burkholderia mallei, and Pseudomonas aeruginosa and the Gram-positive
agent Streptococcus pneumoniae.17,18,101,113-115 In K.pneumoniae and E.coli models, MCP-1-/mice had increased bacterial burden, decreased neutrophil influx, and attenuated
cytokine/chemokine production and NF-κB and MAPK activation following infection as
compared to C57Bl/6 mice. Furthermore, through the use of migration experiments and flow
cytometry, it was shown that neutrophils present in blood and lung express the CCR2
receptor and migrate in response to MCP-1.17 In a similar study, E.coli endotoxin or MCP-1
were administered as sole agents, or given in concert to immunocompetent Balb/c mice.
MCP-1 given alone elicited monocyte recruitment without increasing pro-inflammatory
cytokines, whereas E.coli endotoxin caused neutrophil influx and increases in proinflammatory cytokines (IL-6, TNFα) and the neutrophil chemokine MIP-2 at the 6 hour time
point.113 Interestingly, co-administration of MCP-1 and E.coli endotoxin intratracheally
resulted in marked increase in pro-inflammatory cytokines/chemokines and a 22-fold higher
neutrophil lavage concentration than with endotoxin administration alone, supporting the
idea that MCP-1 may be exerting some of its neutrophil chemotactic and pro-inflammatory
effects via synergism with endotoxin.113
The role of MCP-1 in innate immune response to Gram-positive bacterial pneumonia
has only been investigated in two studies using various strains of Streptococcus pneumoniae,
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an important pathogen in community-acquired pneumonia. While these experiments differ in
inoculation methods, dosage, strains of S. pneumoniae, and timeline, neither demonstrate a
strong role for MCP-1 in neutrophil chemotaxis or pro-inflammatory cytokine production at
early time points (6-48 hours).101,114 In one study S. pneumoniae was administered
intranasaly at varying dosages with no difference in bacterial CFUs, inflammatory cytokine
profiles or lethality observed over 0-48 hour time points when comparing C57Bl/6 and MCP1-/- mice.114 In a second study, mice were inoculated intratracheally with either a highly
virulent or less virulent strain of S. penuemoniae. While both C57Bl/6 and MCP-1-/- mice
were highly susceptible to the more virulent strain, C57Bl/6 mice were protected from
mortality when challenged with the less virulent strain, as compared to MCP-1-/- mice.101 In
contrast to the K. pneumoniae and E.coli models, this protective phenotype was most likely
conferred by an increased influx of macrophages and dendritic cells observed at later time
points, as no appreciable difference in cytokine/chemokine profile were observed at early
time points and neutrophil concentrations were actually significantly higher in MCP-1-/- mice
at 1 day post-infection.101
From these studies one may speculate that the role of MCP-1 in innate immune
response to bacterial pneumonia is dictated by the presence or absence of lipopolysaccharide,
however other Gram-negative pneumonia models may not support this conclusion. In a B.
mallei pneumonia model both MCP-1-/- and CCR2-/- mice had increased mortality, local
bacterial burdens and dissemination compared to C57Bl/6 mice at 72 hours, however CCR2-/mice had increased neutrophils in the lung tissue, and increased TNFα and KC in lung tissue
at 48 hours post-infection.115
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While the factors dictating how MCP-1 synergizes with pathogens such as K.
pneumoniae and E.coli to produce robust neutrophilic responses remains unknown, a model
of Pseudomonas aeruginosa pneumonia has provided a plausible explanation for models in
which loss of MCP-1/CCR2 has resulted in mild to moderately increased neutrophil influx
and cytokine production, and increased mortality.20 Mice administered anti-MCP-1 antibody
and P. aeruginosa showed increased neutrophilic inflammation, hemorrhage and exudation
in lung tissue, increased neutrophil concentrations and MPO activity in BALF, and
interestingly, decreased efferocytosis as compared to control Abs-treated mice, despite no
differences in BALF macrophage concentrations.20 In vitro work by the same group
demonstrated macrophages co-cultured with MCP-1 and aged neutrophils exhibited
increased phagocytosis of apoptotic cells in a dose dependent manner.20
These findings suggest that in some models of pneumonia increased neutrophil influx,
persistence of MPO activity and increases in inflammatory cytokines may perhaps be due to
a decreased efficiency of macrophages to phagocytize aged neutrophils in MCP-1-/- or ABblocked mice, allowing for continued release of inflammatory mediators from these dying
cells. Central to all of these studies however, is that among the repertoire of pathogens
currently investigated, MCP-1 plays a protective role in innate pulmonary immune responses.
3.2.2.c. Inflammatory and neoplastic disease
MCP-1 and CCR2 are of central importance to many non-infectious disease
processes, with the MCP-1/CCR2 axis proving a promising target for pharmacologic
blockade and therapeutic intervention. In chronic inflammatory diseases the continued
accumulation of macrophages can lead to fibrosis and further end-organ damage. Studies in
humans and rodents have demonstrated that MCP-1 levels correlate with increasing degrees
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of fibrosis in models of pulmonary and renal fibrosis.25 Additionally MCP-1 is central to the
pathogenesis of arteriosclerosis and re-stenosis after vascular injury as it recruits
macrophages to the vessel wall.24 MCP-1 may also be important in many neoplastic
diseases, owing to expression of MCP-1/CCR2 by endothelial cells and tumor infiltrating
macrophages, both key players in neoangiogenesis.26
3.2.3. MCP-1 therapies
Anti-MCP-1 therapies including MCP-1 blocking antibodies and gene therapy have
been developed to moderate chronic or deleterious inflammatory responses, fibrosis,
angiongenesis, and tumor burden.24-26,116 While these therapies contrast in method of
delivery, they are functionally similar, as the end result of gene therapy is incorporation and
transcription of a DNA sequence encoding for a non-functional MCP-1 competitive
antagonist.25 To date parenteral administration of anti-MCP-1 antibodies have been utilized
in a number of animal trials as well as a human trial for treatment of rheumatoid arthritis,
while gene therapy has only been used in animal models.24-26,116 Collectively these trials
have produced many promising results including decreasing intimal proliferation in
artheriosclerotic plaques, reducing vessel restenosis post-angioplasty, decreasing organ
fibrosis, and reducing overall tumor burden and angiongenesis in cancer models24-27 As
these therapies progress towards human clinical trials, understanding the role of MCP-1 in
innate immune defenses and delineating important risk factors for patients receiving such
treatments becomes a priority.
3.3. Staphylococcus aureus
Staphylococcus aureus is a Gram-positive bacterial cocci that can be both a
commensal or invasive pathogen in humans. Microscopically S. aureus appears in clusters,
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and when cultured can be differentiated from other types of staphylococci by positive
coagulase, mannitol fermentation, and deoxyribonuclease testing.117 While capsular antigens
can be used to serotype S. aureus, pulse-field gel electrophoresis (PFGE) is considered the
method of choice for determining bacterial strain.3,117 For the purposes of simplifying
nomenclature, the CDC assigned strain names to S. aureus based on PFGE results from
common isolates within the United States (ie the USA strains).3 Originally 8 strains were
identified but this number has since grown ranging from USA100-USA1200.3 Notably the
majority of these are methicillin resistant (ie MRSA) with the exception of strains USA900
and USA1200.3
3.3.1. Ecology and epidemiology
The human nares are a well-documented site for S. aureus colonization and much of
our data concerning prevalence of S. aureus colonization come from epidemiologic studies of
nasal carriage.25,118-120 In one such study conducted in the United States from 2001-2004
approximately 30% of subjects had nasal colonization with S. aureus, however a relatively
low number of these cases were due to colonization with a MRSA strain (0.8-1.5%).120
Colonization with S. aureus has long been considered a risk factor for development of
invasive disease; although only a low number of those with nasal carriage go on to develop
infection.118-120 The majority of S. aureus infections occur in the skin and soft tissues, but
other manifestations such as pneumonia and septicemia constitute a substantial cause of
MRSA mortality.117 In 2005 MRSA strains were responsible for 18,000 deaths in the United
States, greater than 75% of which were caused by pneumonia.2 While within a hospitalized
setting comorbidity such as underlying disease, immunosuppression, or recent surgery play a
role in development of infection, community acquired cases often occur in healthy
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individuals with no apparent risk factors.3,13,119 Given the dissimilarities between community
and hospital acquired S. aureus infections, they are addressed individually below with a
predominate focus on MRSA.
3.3.1.a. Community acquired MRSA
Community acquired MRSA (CA-MRSA) refers to cases that lack an association
with health care. Other traits that typify CA-MRSA often include PFGE type USA300 and
genes encoding certain virulence factors that are often expressed by, but not specific to,
USA300.3,119,120 In addition, while the name itself implies resistance to β-lactam antibiotics,
CA-MRSA strains are generally susceptible to a wider range of antibiotics than hospital or
ventilator acquired strains (HA/VAP-MRSA).119,121 USA300 was recognized as a
predominant cause of CA-MRSA in the late 1990s and early 2000s, before which USA400
was the most frequent isolate.3,119 While these outbreaks often occurred among seemingly
healthy individuals including members of sports teams and military units, these cases did
highlight potential risk factors including shared use of personal items (towels/razors),
previous antibiotic use, or ineffectual wound care.3 A multi-institutional survey conducted in
2006 indicated MRSA strain USA300 to be the leading cause of skin and soft tissue
infections among emergency room patients.11
While USA300 less commonly causes pneumonia, when it occurs, it is often severe,
necrotizing and fatal. The necrotizing and hemorrhagic features of USA300 pneumonia are
well-documented, however a conserved mechanism to explain development of these lesions
has yet to be delineated.7 A commonly implicated contributor is Panton-Valentine
leukocidin, a virulence factor expressed by many USA300 isolates, but other factors are
likely at play, as strains not expressing this virulence factor have been documented to cause
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similar lesions.8 For individuals developing MRSA as a result of compromised immunity
after influenza infection, interferon may play an important role.13 In murine models severe S.
aureus pneumonia can be induced at lower inoculum dosages in animals previously infected
with influenza.122 Additionally mice deficient in interferon-α/β receptor 1, which are
incapable of responding to interferon, were protected from a lethal challenge with S. aureus
as compared to wild type mice.16
3.3.1.b. Hospital/Ventilator acquired MRSA
Hospital acquired MRSA (HA-MRSA) and ventilator acquired pneumonia due to
MRSA (VAP-MRSA) pose a significant health risk to hospitalized populations, with reported
mortality rates as high as 37%.4 Prior to the rise of USA300 in CA-MRSA, commonly
isolated HA-MRSA strains included USA100, USA200, and USA500.119 While both CA
and HA-MRSA strains are resistant to methicillin, the genetic determinants which confer this
resistance differ, with HA-MRSA strains often showing resistance to a wider array of
antibiotic classes.119,121 As USA300 continues to be the most prevalent cause of CA-MRSA
cases, these distinctions are becoming less clear and growing epidemiologic evidence
supports that USA300 is also now a leading cause of HA-MRSA.4 In 2012, MRSA isolates
from 251 intensive care unit (ICU) patients were obtained and while USA100 predominated
(55%), USA300 was the second most common isolate (23.9%).4
Compared to HA/VAP caused by methicillin sensitive strains, HA/VAP MRSA is
documented to have increased mortality, and is responsible for increased utilization of
hospital resources and cost burden, with treatment of MRSA cases averaging $8,000 more
than MSSA cases in one retrospective.5,6 Infection with HA/VAP may occur in patients with
nasal colonization, although transient skin colonization of health care workers and patients is
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also a proposed mode of transmission. Interestingly a genotypic determinant named arginine
catabolix mobile element (acme) present in some isolates of USA300 may improve fitness
and increase the ability of the organisms to remain on the skin by encoding an arginine
deaminase, which allows for the formation of ammonia. This pathway may allow USA300
to maintain its pH in the relatively acidic environment of human skin.123 If this is indeed the
case, much of our current epidemiologic investigations involving MRSA may be far from
complete, as they focus largely on screening via nasal carriage.
3.3.2. Major virulence factors
3.3.2.a. Protein A
Protein A (Spa) is a well-studied and abundant S. aureus surface protein. Although
Spa serotyping was often employed in older epidemiological studies of S. aureus, this has
largely been surplanted by newer molecular techniques. While PFGE is the gold standard for
classification of S. aureus strains the Xr region of spa is highly genetically diverse, and
provides the basis for spa typing.13 Immunologically, the Xr region is responsible for
promoting a type I interferon response. Spa encoding strains have been shown to induce
IFN-β production in pulmonary epithelial cells.16 Interestingly this type I interferon response
increases the pathogenicity of S. aureus in the context of pneumonia, as demonstrated by
Ifnar-/- mice which are protected from lethal S. aureus challenge as compared to wild type
mice.13 These findings provide some mechanistic support for the long held observation that
individuals acquiring S. aureus pneumonia as a sequel to influenza, a potent inducer of the
type I interferon response, suffer dramatically increased morbidity and mortality.13
Spa is equipped with 5 IgG binding domains that bind the Fc component of IgG.
These structures have proven useful experimentally, as they provide the basis for
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immunoprecipitation experiments, however conflicting information exists as to if coating
with IgG protects the organism from phagocytosis as originally thought.13 Spa is also
capable of binding immunoglobulin receptors, notably the B-cell IgM receptor, which has
earned it the term B-cell super antigen.124 Binding of the B-cell IgM receptor is believed to
cause rapid clonal expansion and apoptosis of B-cells, ultimately resulting in the inability to
mount an effectual B-cell response to the organism.13
The IgG binding domains mentioned above are relatively promiscuous, and have also
been demonstrated to bind TNFR1, EGFR, and ADAM17.125-127 Binding of TNFR1 induces
TNF production, where as binding to EGFR can lead to cleavage of TNFR-1 and ADAM17
binding produces soluble proteins that neutralize IL-6.126,127 Thus, depending on the context,
spa can generate both pro and anti-inflammatory cytokine responses.
3.3.2.b. α-Hemolysin
α-Hemolysin (Hla) is a ubiquitously expressed S. aureus heptameric pore-forming
toxin which penetrates eukaryotic lipid bilayers. It is a well-documented contributor to S.
aureus induced lung pathology, with a broad range of target cells including histiocytes,
epithelial cells and endothelial cells.13 The cellular receptor for α-Hemolysin, ADAM-10, is
a matrix metalloproteinase which regulates cellular adhesion and mobility.128 The HlaADAM10 interaction has been shown experimentally to disrupt focal cellular adhesions and
integrin signaling in epithelial cells and cause vascular endothelial-cadherin cleavage and
loss of endothelial barrier function.128,129 This relationship may explain some of the
pathology induced by α-Hemolysin including pulmonary hemorrhage and edema formation.13
Additionally it provides a putative mechanism for S.aureus dissemination throughout the
lung, as well as systemically, via interaction with endothelial cells, granting the organism

!
!

46

access to the blood stream.128,129 Regardless of the exact mechanisms, experimental evidence
supports the important contribution of this interaction to lung pathology, as ADAM-10-/- mice
were found to be significantly less susceptible to fatal S. aureus pneumonia as compared to
wild type mice.13 α-Hemolysin also serves as a ligand for the NLRP3 inflammasome, leading
to induction of IL-1β and IL-18 production and pyroptosis.75
3.3.2.c. Panton-Valentine leukocidin
Panton-Valentine leukocidin (PVL) is a pore-forming toxin shown to cause apoptosis
of neutrophils in low doses and neutrophil necrosis in high doses. These effects appear to
vary with species, and have been demonstrated in humans and rabbit models, where as
murine neutrophils appear relatively resistant.9,10 In addition to inducing inflammation via
leukocyte necrosis, PVL has been shown experimentally to induce transcription of genes
encoding for pro-inflammatory cytokines in alveolar macrophages. PVL mediated gene
transcription occurs in an NF-κB mediated manner, resulting in upregulation of TNF-α and
MIP2.130 This function appears to be mediated via binding of PVL to TLR2, and occurs
independent of its pore forming capabilities.130
While by no means pathognomonic, the severe necrotizing and hemorrhagic
pneumonia seen in many cases of CA-MRSA is characteristic of USA300 infection. PVL,
which is expressed by a large number of USA300 isolates, and by relatively few other MRSA
or MSSA strains, has often been implicated as a major cause of these pathologic changes.8,9
It is unlikely, however, to be the sole mediator, as similar pathologic lesions are described
post-infection with USA300 strains not expressing PVL.8 Furthermore, conflicting
information exists as to PVL expression and clinical outcome. Another virulence factor that
may contibute are phenol soluble modulins (PSMs). PSMs have been shown experimentally
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to have similar leukocytic effects, which may also be relevant in a broader range of host
species.9,11
3.3.2.d. Super antigens
Super antigens (SAgs) are molecules that stimulate T-cell hyperactivation resulting in
massive cytokine release, and underpin the pathogenesis of toxic shock syndromes associated
with certain strains of Staphylococcus and Streptococcus. SAgs exert this effect by
sidestepping traditional antigen presentation, and bind MHC class II molecules of antigenpresenting cells and the variable region of the T-cell receptor β-chain simultaneously.12 This
allows SAgs to activate all T-cells expressing a Vβ-TCR (as much as 50% of cells) rather
than the 0.01% of T-cells that would normally respond to an antigen.12 While most described
SAgs are small-secreted molecules encoded on mobile elements with variable strain
expression, recently staphylococcal enterotoxin like toxin (Selx) has been discovered, which
is a super antigen encoded by the core genome of over 95% of S. aureus strains, including
MRSA 300. Expression of Selx by USA300 does appear to interact with the Vβ-TCR, and
contribute to the necrotizing pneumonia characteristic of USA300 in a rabbit model of
pneumonia.12
3.3.3. Host immune response
Various cell wall components of S. aureus (peptidoglycan, lipoteichoic acid,
lipoprotein) are recognized by PRRs including TLR2, NOD2 present on resident epithelial
cells and alveolar macrophages, as well as by the soluble PRRs mannose binding lectins and
ficolins.14 While association with lectins and ficolins marks S. aureus for complement
mediated destruction it may prove ineffectual as the bacteria encodes many complement
blocking proteins.13 Additionally, while mice deficient in the TLR2 adaptor protein MyD88
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are highly susceptible to systemic infection with S. aureus, these mice are able to control
pulmonary infection with maintained cytokine/chemokine and neutrophil responses.14 In
contrast NOD2-/- mice challenged intratracheally with S. aureus do have diminished
cytokine/chemokine responses and neutrophil influx, however, reduced inflammatory
signaling in this model lead to improved bacterial clearance.15 These findings illustrate the
complex interaction between the pathogen and host, and stress the necessity of in vivo
models to assess the true relative contributions of putative immune players.
While undoubtedly some degree of pro-inflammatory signaling is necessary for
bacterial clearance and neutrophil recruitment, it remains unclear which signaling cascades
are vital, dispensable, or actually counter productive for protective immunity. Despite its
role in neutrophil chemotaxis and ability to augment neutrophil and macrophage mediated
microbe killing, higher TNF-α concentrations are not necessarily protective. In one study
TNF-α levels were inversely correlated with outcome in an S. aureus pneumonia model.13
Likewise mice deficient in TNFR1 clear S. aureus more efficiently than wild type mice,
however this effect may be mediated by decreased binding of not only TNF- α, but also
Protein A, an S. aureus virulence factor known to bind and signal through this receptor.16
Numerous S. aureus derived antigens such as capsular antigens, staphylococcal
enterotoxin A and B, and lipoteichoic acid, as well as host derived substances such as the
complement component C5a contribute to neutrophil chemotaxis and induction of IL-8.1 In
addition to IgG binding domains of protein A and complement inhibitors encoded by S.
aureus preventing its phagocytosis, the bacteria also encodes proteins that promote its
survival post phagocytosis. These include the pore forming HLA or PVL that can liberate
the organism from phagocytic cells, and catalase and proteases to combat both oxygen
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dependent and independent killing.1 Additionally phagocytosis of S. aureus can accelerate
apoptosis of neutrophils, resulting in secondary lysis of neutrophils and release of their
inflammatory contents prior to efficient efferocytosis by macrophages.1
Regardless of these varied immune evading techniques organisms are none the less
readily phagocytized and killed by neutrophils, and there is long standing evidence
supporting the critical role of neutrophils in clearance of S. aureus from the lungs. This point
is illustrated in people afflicted with immune-deficiencies involving neutrophil function, such
as chronic granulomatous disease and hyper IgE syndromes, in which the incidence of
recurrent and unresolving S. aureus infections are well-documented.1 Left unchecked,
however, neutrophils can impart as much harm to the surrounding tissue as to the pathogen
via toxic mediators such as elastase, collagenase, and free radicals.1 The factors delineating
what constitutes a protective versus harmful immune response to S. aureus continue to be
elusive, warranting further studies into the pulmonary innate immune response to this
important pathogen.
3.3.4. Animal models
The majority of in vivo animal studies have been performed in mice.13 Given the
ready availability of specific gene deficient strains, murine models have offered much insight
into immunologic responses during S. aureus infection. One major limitation of the murine
model is the relative resistance of mice to S. aureus infection, developing only mild disease
at doses of 1x108 CFU/ml, with as much as 3-4x108 CFU/ml constituting a “high dose”
causing significant mortality.131 Additionally while PVL causes neutrophil influx to murine
lungs, the toxic pore forming principle does not appear to affect murine leukocytes.130 The
failure of murine models to recapitulate the severity of human USA300 pneumonic lesions
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has lead to the use of a rabbit model. While rabbits also require much higher inoculation
dosages of S. aureus than would be expected in naturally occurring human pneumonia, they
are similarly sensitive to PVL and the T cell superantigen Selx, both of which appear to
contribute to severe hemorrhagic pneumonia in this species.10,12
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CHAPTER 4
MATERIALS AND METHODS
4.1. Mice
8- to 10-week-old female mice genetically deficient in MCP-1 (Jackson
Laboratories) were used, while age- and gender matched C57Bl/6 mice were used as
controls.132 Animal studies were approved by the Louisiana State University Animal Care
and Use Committe. The mice ranged from 19 to 25 g in weight.
4.2. Infection model
Bacteria were prepared for mouse inoculation, as described in previous studies.133
Methicillin resistant S. aureus (MRSA) strain USA300 (from F. DeLeo, Rocky Mountain
Laboratories, National Institute of Allergy and Infectious Diseases, Hamilton, MT) was
grown in Trypticase soy broth (TSB) at 37°C overnight under constant agitation. Bacteria
were harvested, washed, and resuspended in sterile 0.9% saline at a concentration of 20x108
CFU/ml. Mouse strains were anesthetized with intraperitoneal ketamine-xylazine (250
mg/kg), followed by intratracheal (i.t.) inoculation of 50 ul of bacteria (108 CFU/mouse). The
initial mouse inocula were confirmed by plating serial 10-fold dilutions on tryptic soy agar
(TSA) plates. For enumerating bacterial CFU in the lung, liver and spleen, whole spleens and
whole lung and liver lobes were homogenized in 1 ml sterile deionized water for 30 s, and 20
ul of the resulting homogenates was plated by serial 10-fold dilutions on TSA plates.
Bacterial colonies were counted after incubation overnight at 37°C.
4.3. Blocking antibodies
C57Bl/6 mice were treated i.t. with MCP-1 (R&D systems) or IgG2B antibody (10
ug/mouse) 30 minutes prior to S. aureus infection (108 CFUs/mouse).
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4.4. Bronchoalveolar lavage fluid collection
Bronchoalveolar lavage fluid (BALF) was collected, and total and differential cell
counts and cytokine/chemokine levels were determined. Approximately 3 ml of lavage fluid
was retrieved per mouse. Total leukocytes in BALF were determined using a hemocytometer.
Cytospin samples were subsequently prepared from BALF cells and stained with WrightGeimsa. Differential cell counts were determined by direct counting of stained slides. For
examination of cytokines/chemokines, the remainder (2 ml) of the undiluted cell-free BALF
was used immediately or stored at -80°C.
4.5. Cytokine and chemokine ELISA
We used BALF and lungs that were obtained from animals after S. aureus infection
or control animals. Enzyme-linked immunosorbent assay (ELISA) kits for tumor necrosis
factor alpha (TNF-alpha), interleukin-6 (IL-6), Interleukin-1β (IL-1β), Interleukin-17 (IL17), IL-17A, and IL-17F and MCP-1 were obtained from eBiosciences, PA, whereas kits for
KC and MIP-2 and LIX were obtained from R&D Systems, MN. The minimum detection
limit is 8 pg/ml cytokine protein.
4.6. Myeloperoxidase activity assay
Myeloperoxidase (MPO) release by the neutrophils was measured as previously
described.134
4.7. Histopathology
The lungs of C57Bl/6 and MCP-1-/- mice were perfused from the right ventricle of the
heart with 10 ml isotonic saline at 6 hours and 24 hours post-infection. Lungs
were then removed and fixed in 4% phosphate-buffered formalin. Fixed tissue samples were
processed in paraffin blocks, and 5µm sections were cut with a microtome and stained with
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hematoxylin-eosin (H&E). Analysis of histopathology was performed in blinded fashion by a
veterinary pathologist using an amended version of a previously published scoring system
(Table 1) with scores for each category assigned to individual lung lobes based on
microscopic assessment at an objective of x400.135
4.8. Statistics
All statistical calculations were performed using GraphPad Prism (version 5.0)
software. Data are displayed as median and interquartile ranges. Groups were compared
using the Wilcoxon rank-sum test. Differences were considered significant at *p<0.05;
**p<0.01;***p<0.001.
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Figure 5. Quantitative scoring of lung histopathology.
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CHAPTER 5
RESULTS
5.1. MCP-1-/- mice have increased neutrophils in the airways and lung parenchyma post
S.aureus challenge
Recruitment of leukocytes, specifically neutrophils, is an important step in achieving
clearance of S. aureus as well as other bacterial pathogens. To investigate the extent of
leukocyte recruitment to the airways, we determined total and differential leukocyte counts in
BALF at 6 and 24 hours post-infection with S. aureus (108 CFU/mouse). We observed that
both C57Bl/6 and MCP-1-/- mice responded to S. aureus challenge with increased leukocyte
influx at 6 hours with highest concentrations measured at 24 hours, and that in both groups
neutrophils predominated [Figure 6 (6a and 6c)]. Additionally, while total leukocyte and
neutrophil concentrations were similar between experimental groups at 24 hours, MCP-1-/mice had increased numbers of neutrophils at the 6 hour time point [Figure 6 (6a and 6c)].
To assess neutrophil activity and infiltration of lung tissue, a myeloperoxidase activity assay
was performed on lung tissue from MCP-1-/- and C57Bl/6 mice. While both experimental
groups showed increased MPO activity in lung homogenates, with highest activity at 24
hours post-infection, MCP-1-/- mice had significantly higher MPO activity at both 6 hours
and 24 hours [Figure 6 (6a and 6c)]. Intraalveolar inflammation and tissue involvement were
assessed in individual lung lobes from C57Bl/6 and MCP-1-/- mice. Higher scores for
intraalveolar inflammation and tissue involvement were more frequent in lung lobes from
MCP-1-/- mice at 6 hours, at which time 9/10 had a score of 1 for intraalveolar inflammation,
and 9/10 a score of 1 or 2 for tissue involvement, compared to a score of 0 in 9/10 lobes from
C57Bl/6 mice for both intraalveolar inflammation and tissue involvement (Figure 7). At 24
hours post infection scores of 1 and 2 for both intraalveolar inflammation and tissue
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involvement predominated, and occurred in similar frequency between groups. Alveolar
hemorrhage and congestion of alveolar septae were also evaluated histologically and
appeared similar between groups.

Figure 6. Leukocyte recruitment to airways and lungs of MCP-1-/- mice . A MCP-1-/- mice
have increased concentrations of leukocytes in BALF at 6 hours post S. aureus infection as
compared to C57Bl/6 mice. Both experimental groups have increased concentrations of
leukocytes in BALF post- infection as compared to negative controls (NC) (levels of
significance not graphically displayed). B MCP-1-/- mice have increased myeloperoxidase
(MPO) activity in lung tissue at 6 and 24 hours post S. aureus infection as compared to
C57Bl/6 mice. Both experimental groups have increased MPO activity as compared to
negative controls (NC) (levels of significance not graphically displayed). C Representative
cytocentrifuged preparation of BALF from a C57Bl/6 mouse (top) and MCP-1-/- mouse
(bottom) 6 hours post S. aureus infection. 50x objective, Wright-Geimsa (WG). Inset: a
neutrophil containing clusters of bacterial cocci. 100x objective WG.
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Figure 7. Lung histology in MCP-1-/- mice following S. aureus infection. Mice were
inoculated with S. aureus (108 CFU/mouse), lungs were obtained at 6 hours post-infection.
This picture is a representative of 2 separate mice with comparable results.
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5.2. MCP-1-/- mice have increased levels of inflammatory cytokines at 6 hours post S. aureus
infection
Numerous cytokines and chemokines produced during inflammation can exert effects
on neutrophil dynamics and recruitment. Since neutrophil recruitment appeared enhanced at
the 6 hour time point in MCP-1-/- mice, we examined the concentrations of many known
inflammatory mediators of neutrophil recruitment in BALF and lung tissue. We found
increased concentrations of the inflammatory cytokines TNF-α and IL-6 in MCP-1-/- mice at
the 6 hour time point (Figure 8). IL-1β increased in both experimental groups with infection
but was not significantly different between groups. The neutrophil chemoattractant
chemokines KC, MIP-2, and LIX increased with infection and LIX concentration were
significantly higher in MCP-1-/- mice 24 hours post-infection (Figure 8).
5.3. Local bacterial burden and dissemination are equivocal in MCP-1-/- and C57Bl/6 mice
While adequate neutrophil recruitment is a proven necessity in bacterial clearance,
protective immunity does not always correlate directly to neutrophil numbers. In some
models excess neutrophil accumulation and/or pro-inflammatory cytokine production are
accompanied by poor prognosis and outcome in S. aureus infection.1 For this reason we
assessed both local bacterial burden and dissemination as determined by bacterial load in
BALF, lung, liver and spleen. Mice were infected with S. aureus i.t. and sacrificed at 6 and
24 hours post-infection and BALF, lung, liver, and spleen were collected to quantitate
bacterial CFUs. While both experimental groups had highest bacterial burdens in BALF and
lung at 6 hours that decreased at the 24 hour time point, MCP-1-/- mice had significantly
fewer bacterial CFUs in BALF at 6 hours as compared to C57Bl/6 mice (Figure 9).
Dissemination to the liver and spleen was present at 6 hours and persisted at 24 hours in both
groups (Figure 9).
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Figure 8. Cytokine and chemokine profile in MCP-1-/- mice. A Cytokine Profile. MCP-1-/mice have increased concentrations of IL-6 and TNF-α in BALF at 6 hours post- infection
compared to C57Bl/6 mice. Experimental groups have increased concentrations of IL-6 and
TNF-α as compared to negative controls (NC) (levels of significance not graphically
displayed, IL-6 and TNF-α NC below detection limit). IL1-β levels increase with infection
but are not different between experimental groups (levels of significance not graphically
displayed). B Chemokine Profile. MCP-1-/- mice have higher levels of LIX at 24 hours postinfection compared to C57Bl/6. MIP-2 levels are higher in negative control C57Bl/6 than
MCP-1-/- mice. For both groups KC and MIP-2 increase significantly at 6 hours and decrease
significantly by 24 hours, whereas LIX continues to increase at 24 hours post-infection
(levels of significance not graphically displayed, KC below limit of detection for NC).
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Figure 9. Bacterial burden in MCP-1-/- mice. MCP-1-/- mice have lesser numbers of bacterial
CFUs in BALF at 6 hours post S. aureus infection as compared to C57Bl/6 mice. BALF and
lung CFUs decrease in both experimental groups 24 hours post- infection. Bacterial
dissemination is present in liver and spleen at 6 hour and 24 hour time points.
5.4. MCP-1 AB-blocked mice trend towards higher BALF leukocyte concentrations and lung
MPO activity
The same infection model was performed using MCP-1 and isotype control ABblocked mice to ensure that the MCP-1-/- phenotype correlated with that of MCP-1 AB
blocked animals. MCP-1 AB blocked mice trended towards higher total leukocyte
concentrations in BALF and higher MPO activity in lung tissue, despite similar CFU in
BALF and lung homogenates (Figure 10). A cytokine/chemokine profile including IL-6,
TNF-α, IL-1β, KC, MIP2, and LIX revealed no significant differences between groups, with
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the exception of LIX, which was higher in MCP-1 AB blocked mice at 6 hours post-infection
(Figure 11).

Figure 10. Neutrophil recruitment to the lungs and airways and local bacterial burden in
MCP-1 AB-blocked mice. MCP-1 AB blocked mice trend towards higher leukocyte counts
in BALF and higher MPO activity in lung tissue as compared to AB-blocked control mice.
Bacterial CFUs do not differ between groups, but do decrease significantly by 24 hours postinfection in both experimental groups (level of significance not graphically displayed.)
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Figure 11. Cytokine and chemokine profile in MCP-1 AB-blocked mice. MCP-1 AB blocked
mice have higher levels of LIX at 6 hours post S. aureus infection, while levels of IL-6, TNFα, IL-1β, KC, and MIP2 do not differ between groups.
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CHAPTER 6
DISCUSSION
Adequate neutrophil recruitment to the lungs and airways is vital for protective
immunity against a number of pulmonary pathogens including S. aureus. In E.coli and K.
pneumoniae models MCP-1 enhances neutrophil recruitment and bacterial clearance,
however in our model MCP-1-/- mice had higher neutrophil numbers in BALF, and increased
MPO activity in lung tissue, with no appreciable improved bacterial clearance.17,18 A number
of other pneumonia models support increased neutrophil influx to the lungs and increased
pro-inflammatory cytokine profiles in MCP-1-/- or CCR2-/- mice including studies with the
gram negative pathogen Burkholderia mallei and the gram positive pathogen S. pneumoniae.
Interestingly, MCP-1 was still protective in these models, with knock out mice demonstrating
increased mortality and bacterial burden as compared to wild type controls.101,115 Unlike in
the E.coli and K. pneumoniae models, however, the protective role of MCP-1 appeared to be
via recruitment of macrophages to airways at later time points, rather than an effect on
neutrophil recruitment.
Increased numbers of neutrophils present in the airways and lungs of MCP-1/CCR2-/mice may be the result of one or more of three general mechanisms. Firstly MCP-1/CCR2-/mice may produce an altered inflammatory signaling cascade during certain infections
leading to the generation of increased neutrophil chemotactic molecules as compared to wild
type mice. Second, neutrophil lifespan may be prolonged/enhanced in the absence of MCP1/CCR2. Thirdly MCP-1/CCR2-/- mice may have impaired clearance of senescent
neutrophils.
In our model IL-6 and TNF-α concentrations were higher in MCP-1-/- mice, but
neutrophil chemotactic substances (KC, MIP2, LIX) were not significantly different between
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groups, with the exception of higher LIX in MCP-1-/- mice at the 24hr time point, and higher
MIP2 in C57B/l6 mice at baseline. Ultimately, however, sample collection at the 4 hour time
point would have been ideal to asses if neutrophil chemotactic molecules were higher in
MCP-1-/- mice prior to the increased influx of neutrophils to the lung and airways noted in
this group at 6 hours. The increased concentration of LIX at the 24 hour time point may
simply reflect the slower kinetics of this chemokine compared to KC and MIP2 as has been
previously reported.136 A biological reason for the difference in MIP2 between control
groups is less evident, and may simply be a statistically relevant but biologically irrelevant
difference, reflective of low sample size.
While chemokine receptors generate many down-stream signaling cascades, no
experimental evidence currently exists to support the conclusion that neutrophil lifespan is
regulated via the MCP-1/CCR2 axis, or would be enhanced in the absence of MCP-1/CCR2
signaling, making this scenario less likely. There is, however, currently experimental support
that MCP-1 deficient mice demonstrate decreased efferocytosis of senescent neutrophils,
which may contribute to secondary necrosis of these cells, prolonging both pro-inflammatory
signaling and neutrophil number and MPO activity in tissue.
Mice administered anti-MCP-1 antibody and P. aeruginosa showed increased
neutrophilic inflammation, hemorrhage and exudation in lung tissue, increased neutrophil
concentrations and MPO activity in BALF, and interestingly, decreased efferocytosis as
compared to control Abs-treated mice, despite no differences in BALF macrophage
concentrations.20!!In vitro work by the same group demonstrated macrophages co-cultured
with MCP-1 and aged neutrophils exhibited increased phagocytosis of apoptotic cells in a
dose dependent manner.20 These findings suggest that in some models of pneumonia
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increased neutrophil influx, persistence of MPO activity and increases in inflammatory
cytokines may perhaps be due to a decreased efficiency of macrophages to phagocytize aged
neutrophils in MCP-1-/- or AB-blocked mice, allowing for continued release of inflammatory
mediators from these dying cells.
While our model shares similarities with some of those previously mentioned (S.
pneumoniae, B. mallei, P. aeruginosa) in terms of immune response generated, these
experiments also demonstrated increased bacterial burden and/or mortality in MCP-1/CCR2-/mice, findings that were not present in our study. One explanation for this is the relative
resistance of mice to S. aureus pneumonia. The inoculum dose used in this experiment
(1x108 CFU/mouse), which would be exceedingly high for other important pulmonary
pathogens such as K. pneumoniae or S. pneumoniae, is considered a low i.t. dose of S. aureus
for mice.131 This is consistent with other pulmonary inoculation models in which S. aureus
doses of 3-4x108 CFU/mouse are considered a high dose inoculum resulting in significant
mortality.131 If high dose inoculum had been used in the current experiment, it may have
allowed for significant differences to emerge between MCP-1-/- and C57Bl/6 mice with
respect to bacterial burden and tissue damage as assessed histologically.
The experimental protocol used in MCP-1-/- and C57Bl/6 mice was also performed in
antibody-blocked mice for two main reasons. First, administration of anti-MCP-1 antibody
has more translational relevance, as it is most similar to the techniques currently employed in
experiments assessing efficacy of anti-MCP-1 antibodies and gene therapy. Second,
correspondence between MCP-1-/- and antibody blocked phenotypes supports the conclusion
that differences present between experimental groups are directly related to MCP-1/CCR2
signaling, rather than any intracellular alterations in gene expression, transcription, or
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translation of proteins that may be occurring in MCP-1-/- as a results of gene deletion. While
antibody blocked mice did not recapitulate the phenotype of MCP-1-/- mice, BALF leukocyte
concentration and MPO activity in lung tissue did trend in similar directions, and LIX was
significantly higher in MCP-1 AB blocked mice at the 6 hour time point. We originally
attempted antibody blocking at a dose of 1ug/mouse and did not observe this trend (data not
shown) supporting the concept that 10 ug/mouse may still be a suboptimal dose of blocking
antibody. Ultimately we expect that MCP-1-/- and AB-blocked phenotypes correspond, as
this has been demonstrated in other models. However to date these experiments have
employed systemic administration of Anti- MCP-1 antibody, and an effective intrapulmonary
dose remains to be described.20
Ultimately how MCP-1 is differentially regulated in models of pneumonia, causing
robust and protective neutrophil influx in K. pneumoniae and E. coli models while absence of
MCP-1/CCR2 in other models results in ineffectual bacterial clearance despite augmented
neutropilic responses, remains unclear. Central to all of these studies however, is that among
the repertoire of pathogens currently investigated, MCP-1 plays a protective role in innate
pulmonary immune responses. It is likely that MCP-1 plays a protective role in pulmonary S.
aureus infection as well, however further studies are warranted; both to more clearly
delineate the pathology in MCP-1-/- mice using a higher S. aureus inoculation dosage, and
also to investigate the putative role of MCP-1 in efferocytosis in this model.
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